AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

AstraZeneca’s (LON: AZN) experimental drug baxdrostat lowered blood pressure in patients with hard to treat hypertension, ...

AstraZeneca has announced that its Baxdrostat hypertension treatment met the primary and secondary endpoints in a Phase III ...

(Alliance News) - AstraZeneca PLC on Monday said a test of its baxdrostat drug showed a "meaningful reduction" in hypertension. The Cambridge, England-based pharmaceutical and biotechnology firm ...

The latest investor updates on stocks that are trending on Monday.

AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor - The UK is ‘a hostile environment’ for ...

Shares of AstraZeneca PLC AZN shed 1.66% to £104.50 Friday, on what proved to be an all-around dismal trading session for the ...

AstraZeneca PLC closed 20.63% short of its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

AstraZeneca 's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of ...